Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo.
Open Access
- 1 April 1991
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 173 (4) , 889-897
- https://doi.org/10.1084/jem.173.4.889
Abstract
We have investigated the effect of granulocyte colony-stimulating factor (G-CSF) delivery at the site of tumor growth by transducing, via retroviral vector, the human (hu) G-CSF gene into the colon adenocarcinoma C-26 and assaying the ability of transduced cells to form tumors when injected into syngeneic mice. As a control, the same tumor cells were infected with retroviruses engineered to transduce an unrelated gene, the human nerve growth factor receptor, or carry the neomycin resistance gene only. Only cells transduced with the huG-CSF were unable to develop tumors, although huG-CSF was expressed and produced at low level as estimated by both RNA analysis and enzyme-linked immunosorbent assay, indicating that G-CSF can exert an antitumor effect at a physiological dose. Implication of G-CSF as mediator of tumor inhibition was proven by reversing the nontumorigenic phenotype of G-CSF-expressing cells with anti-huG-CSF monoclonal antibody injected at the tumor site. No tumors were formed by injecting C-26 infected cells into nu/nu mice, while neoplastic nodules appeared after injection into sublethally irradiated mice; such tumors, however, regressed when mice normalized their leukocyte counts after irradiation. Tumors were also formed after injection of a mixture of infected and uninfected C-26 cells, although critical delay in tumor formation occurred when infected cells were 10 times more represented in the mixture. Histological examination of tissues surrounding the site of injection showed infiltration of neutrophilic granulocytes, whose number correlated with that of G-CSF-expressing C-26 cells in the injected mixture. These results indicate that G-CSF may have a potent antitumoral activity when released, even at low doses, at the tumor site. The antitumoral effect is mediated by recruitment and targeting of neutrophilic granulocytes to G-CSF-releasing cells.Keywords
This publication has 30 references indexed in Scilit:
- Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor responseCell, 1990
- Long-term exposure to retrovirally expressed granulocyte-colony-stimulating factor induces a nonneoplastic granulocytic and progenitor cell hyperplasia without tissue damage in mice.Journal of Clinical Investigation, 1989
- Murine interleukin-4 displays potent anti-tumor activity in vivoCell, 1989
- Immunotherapy of cancer using interleukin 2: current status and future prospectsImmunology Today, 1988
- Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the UrotheliumNew England Journal of Medicine, 1988
- Induction of neutrophilic granulocytosis in mice by administration of purified human native granulocyte colony-stimulating factor (G-CSF)Biochemical and Biophysical Research Communications, 1986
- Expression and structure of the human NGF receptorCell, 1986
- Identification of the human analogue of a regulator that induces differentiation in murine leukaemic cellsNature, 1985
- Role of cell surface contact in the kinetics of superoxide production by granulocytes.Journal of Clinical Investigation, 1983
- Isolation of biologically active ribonucleic acid from sources enriched in ribonucleaseBiochemistry, 1979